CATO SMS has announced that it has acquired Array Biostatistics to expand its offering of specialized clinical research solutions. The company plans to invest in growing Array and its biostatistical capabilities.
Both Array and CATO SMS offer highly specialized services that aim to expedite and support drug development for small and emerging biopharmaceutical companies. By acquiring Array, CATO SMS adds expertise and scale to its full-service biostatistical consulting, analysis and programming capabilities. CATO SMS will focus on growing these capabilities and its team of senior biostaticians and statistical programmers, as it continues to expand its product development consulting and clinical trial operations. Sandy Ferber, chief executive officer of Array, will continue to lead Array and will spearhead CATO SMS’ overall biometrics offering.
“We are thrilled to have this opportunity to grow our biostatistical offering in partnership with CATO SMS. Together, we share core values centered around high quality and a commitment to providing our clients with expert and highly personalized service,” said Ms. Ferber.
Mark A. Goldberg, MD, executive chairman, CATO SMS, added, “We are excited to welcome Array’s impressive team to CATO SMS. The Array acquisition furthers our goal of providing our clients with a comprehensive portfolio of specialized solutions to best support development in complex therapeutic areas including oncology, rare and orphan indications, and cell and gene therapy, among others.”
For more information, read the full release, here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.